Neurosurg Focus 45 (2):E19, 2018 N eurostimulatioN has proven effective for many diseases, including Parkinson's disease 11 and essential tremor, 23 and has shown promising results for newer targets, including chronic pain, obsessive-compulsive disorder, 19 refractory depression, 34 and, most recently, neurocognitive disorders. 12, 37 As advances in neuromodulation continue, its promise grows in remedying various neurological ailments. At this time, deep brain stimulation (DBS) devices consist of surgically implanted leads passed, using the assistance of neuronavigation, through the cortical surface to rest in deep brain structures. MRI, awake-craniotomy procedures, or microelectrode recordings are utilized to ensure that the lead penetrates the correct area of the neural network. The lead is then tunneled under the galea and connected to a generator implanted subcutaneously. While DBS systems have greatly advanced in electrode design and patterns of stimulation, 20 common DBS systems today such as the Activa PC (Medtronic) still rely on a transcranial lead connected to a battery. Wireless systems have been proposed in theory and reported on, but they still necessitate a transcranial lead. 28 Nonincisional alternatives to DBS also exist: techniques such as focused ultrasound 30 and Gamma Knife radiosurgery 26 provide therapeutic results via a nonsurgical lesionectomy within their targets. One drawback of these noninvasive therapies is the finality of the lesion that is created. Even these nonsurgical therapies, however, can result in unwanted neurological deficits. One study of 209 patients in whom the Gamma Knife was used to treat the ventral intermediate thalamic nucleus reported a 6.9% rate of both transient and permanent complications. 58 While the complications of DBS are low in comparison to other procedures, there is risk for permanent neurological damage. 13 Long-term hardware complication rates associated with DBS are reported to be 8.4% per electrode/ year. 39 Major surgical complication rates for DBS lead insertion include a 3.3% risk of hematoma of any type per lead implanted and a 0.6% risk of major neurological deficits. Hemorrhage rates have been shown to correlate with the number of electrode passes. 2 Thus, while DBS systems ABBREVIATIONS DBS = deep brain stimulation; EEG = electroencephalographic; PED = Pipeline embolization device.
continue to advance in design, safety, and effective modulation of their chosen target, new techniques utilizing minimally invasive lead placement should be trialed. This review will discuss the progress made in endovascular lead delivery, stentrodes (stents with the ability to record or stimulate surrounding tissue), and their application to DBS, responsive neural stimulation, and neuromodulation.
Endovascular Delivery of Leads
Many intracranial pathologies are treated using catheter-based techniques utilizing the vascular network largely via a transfemoral artery or vein approach. Stents are delivered for the treatment of wide-necked aneurysms, 3 stenosis, 17 and repair of vessels. Similarly coils, particles, and liquid embolic agents are also delivered into the intracerebral vessels for the treatment of aneurysms, arteriovenous malformations, arteriovenous fistulas, and hypervascular tumors. There are now numerous guide catheters, intermediate catheters, and microcatheters or wires capable of safely delivering devices of many sizes in awake 44 or anesthetized patients. Benefits of endovascular delivery of devices include avoiding craniotomy, faster recovery times, and possibly less patient anxiety. There are numerous patents listed for endovascular cranial lead insertion, 52 stentbased lead anchors, 4 and disease-specific systems. 53 An interesting article by Robert Ritter published in 2017 (https:// www.linkedin.com/pulse/neurovascular-approach-deepbrain-stimulation-robert-ritter-iii) describes a submillimeter nitinol stent anchoring 100 microwires of 0.2-μ thickness capable of accessing very thin capillaries. Watanabe et al. have further studied their vascular microelectrode array in an intravascular spinal cord recording in Xenopus laevis (frog). 54 The electrode material described in the Ritter article proposes iridium oxide, which was initially described by Cogan et al., 10 to increase charge injection, given the small lead size. Wong et al. have also evaluated nitinol electrodes intravascularly for the measurement of visual evoked potentials in sheep. 56 Endovascular placement of leads has successfully allowed for multicellular recording of brain activity. 56 This type of recording or stimulation is necessary as brain activity is composed of coherent multicellular responses best understood via simultaneous recordings from numerous locations. As capillaries permeate every aspect of the brain, creating approximately 25,000 m of vessel, an endovascular approach toward neuromodulation with 10-m vessels coursing in the vicinity of individual neurons, provides a vast network of untapped potential. 32 Ritter hypothesized that the high impedance from endovascularly placed leads (given the decreased lead size) could be overcome by the close proximity of the lead to undamaged neural elements. Discussion of all the possible nanoscale polymers and metal able to create capillary or venulecompatible leads is outside the scope of this review.
This approach has limitations. While stimulation parameters would need to be identified, the placement of many electrodes could provide theoretical advantages in accuracy. Vessel injury or thrombosis is a concern as with any intravascular device, but this would be less of a concern given the small size of such devices. Our best educated guess on device-related effects can be gleaned from Pipeline embolization device (PED; Medtronic) data on flow diversion for the treatment of aneurysms. Metaanalysis data on the PED identified a 5% procedure-related morbidity and mortality rate among 1451 patients. Perforator infarction occurred in 3% of patients, and subarachnoid hemorrhage and intraparenchymal hemorrhage in 3% each. The ischemic stroke rate was 6% (lower in the anterior circulation and higher in the posterior circulation). 7 One caveat to the aforementioned data is that the amount of metal coverage is 33%-35% for PEDs, which is very high, likely indicating the uppermost level of risk for stroke or occlusion. Since the stentrode would not be placed for an aneurysm, the risk of aneurysm rupture would be absent. Neuroform stents used for stent-assisted coiling of aneurysms have 6% metal coverage (much less than the PED). One study examining thromboembolic risks in these stents reported a 0.5% thromboembolism risk (13/237 patients), with 2 patients having late in-stent stenosis. 18 LVIS (low profile visualized intraluminal support) and LVIS Jr. devices have 18%-22% metal coverage, and Iosif et al. reported a 2.2% event rate of sequelae related to the stent. 24 Antiplatelets remain an option, such as aspirin or dual antiplatelet therapy, as currently prescribed for patients receiving intravascular stents. Trials involving stentrodes, as discussed in a later section, have shown similar coagulation profiles to modern stents, 16 further reinforcing the possibility of similar management. New stent coatings are also on the horizon, credited with decreasing the amount of thrombogenicity. One such coating is the SHIELD technology, a phosphorylcholine coating for PEDs. 41 Similar coating technology may prove useful for neurovascular lead design. The stents of today may look nothing like the stents of the future, especially as stentrodes will not have to support coils, hold open plaques, and so on. The structural properties could vary greatly compared to present-day devices.
Achieving an accurate therapeutic location for stentrode placement and the need for retreatment are also concerns. Stent placements can be done in awake patients with intraoperative physiological testing prior to stent deployment. Currently PEDs are deployed in awake patients, 44 and super-selective awake WADA testing can be performed, or test electrodes may be utilized to determine if the desired physiological response is present prior to permanent stent placement. While not optimal, currently stents can be placed over one another when necessary, as in the case with recurrent stent-coiled aneurysms treated with PED flow diversion. 9 Last, anatomical vessel variation may preclude some stentrode placements. Awake physiological testing during angiography will help identify these patients in whom a stentrode should not be placed.
Feasibility of Neurovascular Array Efficacy for Target Disease
Studies of intravascular neuromodulation for both recording and stimulation have described a variety of potential targets for therapeutic management (Table 1) . 25, 27, 37, 42, 46, 49 Teplitzky et al. 49 identified 17 potential DBS targets utilizing a computational model that assessed targets ideal for endovascular DBS stimulation based on neurovascular modeling. They identified 5 targets near a vessel with an intraluminal diameter > 1 mm, suggesting a viable application of endovascular DBS. They also tested the subgenual cingulate white matter and fornix in a computational model of axons to predict the response to endovascular stimulation. Interestingly they concluded that a ring electrode model (stent-like) was more efficient at neural activation than guidewire designed with the length of the ring electrode not correlating to increased efficacy. The study found that endovascular activation thresholds were comparable to DBS lead activation and that contralateral activation was better via a unilateral endovascular approach compared to DBS lead unilateral modeling. Suboptimal placement did, however, affect activation on the endovascular modeling. 49
Stentrodes and Possible Responsive Neural Monitoring
Responsive pacing began with cardiac pacers that use a battery generator to supply leads in the vascular space, responsible for controlling and responding to myocytes and bundle projections. Rates of transvenous lead-induced thrombosis were reported between 0.6% and 3.5%. 1 Intravenous vagal nerve stimulators for cardiac arrhythmias have also been trialed. 50 Electroencephalographic (EEG) recordings from intravascularly placed electrodes date back to 1973, described in baboons by Penn et al. 43 Since that time, endovascular electrode technology has undergone many changes from macro leads, to micro leads on a wire or catheter, and now to nanowire array leads and stentrodes. 45 Responsive technology was only recently applied to the brain with the advent of NeuroPace's RNS System, a responsive neural pacing system that consists of depth leads or cortical grids surgically implanted via craniotomy that are capable of relaying cortical activity and responding appropriately when epileptic activity is detected via tissue stimulation. The device was shown to decrease partial-onset intractable seizures by 44% at 1 year and by 54% at 2 years, in patients in a double-blinded controlled trial. 21 The system does rely on open craniotomy for implantation, but the generator is recessed in the calvaria, thus decreasing the need for lead tunneling.
Currently patents exist for a wireless cardiac pacing system with intravascularly placed leads, 8 and it is likely only a matter of time before this technology is incorporated into cranial products. Briefly, the described patent utilizes a radiofrequency generator to transcutaneously and wirelessly stimulate a receiver on the stentrode, which is then able to convert the radiofrequency into an electrical pulse. Thus, in theory, different stentrodes can be controlled by different radiofrequencies. Integral to this minimally invasive approach would be a stentrode and a transcutaneous/transcalvarial wireless method of exciting such a device. Similar studies utilizing an ultrasound generator and transvenously placed receiver electrode (on a catheter) capable of converting ultrasound energy to electrical energy was demonstrated, in 24 people, to be a safe and feasible way of "wireless" cardiac pacing. 29 Thus, one can explore the concept of placing an electrode on a stent rather than a catheter. The wireless nature of the electrode allows for less thrombogenicity, given the smaller surface area of a foreign body in vasculature and easier, less disturbing placement.
Minimally invasive implantation of cortical recording stents (stentrodes) were reported in 2016 by Oxley et al. 42 The small stentrode was endovascularly placed in the cortical vein of sheep, with demonstrated recording of cortical activity over 190 days. Venous patency was maintained, and vascular corticography data were comparable to those obtained by epidural arrays. A stentrode consisted of platinum discs mounted 2.5 mm apart on a stent-like device, delivered through a 4-Fr catheter via the jugular vein, with the leads anchored at the jugular access site. A cortical vein near the motor area was used, given its relatively constant colocalization with the motor area. Somatosensory evoked potentials were detectable in 98% of channels. 55 Micro-CT and histological evaluation have shown vessel patency and stent strut incorporation into the vessel wall with neointima coverage of 78% at 2-4 weeks. 40 Intravascular electrode recording has also been verified in a swine model to record high-bandwidth, highfidelity electrical correlates of physiological activity. 5 Thus, two types of stentrodes are reported. One utilizes connecting wires, which must be anchored and tunneled as in standard DBS leads. This type of stentrode is more easily seen as working via a jugular vein puncture, as described by Oxley et al., 42 which can decrease the amount of intravascular lead necessary and likely will not be suitable for arterial use. The second wireless stentrode would require microchip circuitry with a transmitting and receiving antenna, similar to that as described by Howard. 22 Similar devices have been described and implanted in cardiac swine models. One such device is a battery-less, wireless, 4 × 1-mm device with a microchip and radiofrequency "on chip" antenna capable of harvesting an external radiofrequency signal at 2-cm tissue thickness. Furthermore, it generates a stimulation pulse signal of 1.3 V. 47 Implantable microchip technology has been trialed in humans previously in the form of a parathyroid drug dispenser that responded wirelessly over medical device frequency. 14 An external generator or receiver would be necessary. In either case, recording and stimulating capabilities would be present. Such adaptive stimulation has been performed with current DBS leads and braincomputer interfacing, leading to a 56% reduction in DBS stimulation time in Parkinson's disease patients. 31
Future Applications of Vascular Stent-Based Technologies
Brancato et al. have described an intravascular pressure-sensing device utilizing piezoelectric technology. They tested the device in carotid arteries of sheep successfully. 6 Thus, the ability to develop multimodality stentrodes is feasible, with devices able to sample electrographic, hematological, and pneumatic stresses. One can imagine the application of a pressure-sensing device implanted into the middle meningeal artery as a viable alternative to intracranial pressure monitors, with little risk of symptomatic morbidity if the artery were occluded. Such a device would aid in trauma patients and shunt-treated patients with the possibility of responsive shunting via programmable valve communication.
Similarly, stents can be made to transmit other signals of physiological relevance. RFID STENTag is a stentrode of sorts described by Occhiuzzi et al. as a radiofrequencytagged stent that can monitor the in-stent stenosis of the carotid artery in correlation with the signal strength emitted. 38 Yanagisawa et al. 57 utilized surgically implanted subdural electrodes in a poststroke patient and were able to demonstrate real-time control of a prosthetic hand. The authors reported that the onset of the hand movement was detected within 0.37 seconds of the actual movement. After electrocorticography decoding, the brain-machine interface used power modulations of the patient's electrocorticography during hand movement. In a free-run period, the patient's hand movements were faithfully mimicked by the prosthesis. 57 Stentrodes would allow a craniotomyfree placement of the leads, and one could conceptualize a type of device in which the patient's own arm could be "innervated" with electrodes, allowing for brain-machinebody interfacing. 33 This type of limb reinnervation could one day help patients with stroke, demyelinating conditions, and spinal cord injury.
Alternating electrical field treatment of tumors, most notably Optune (formerly known as NovoTTF-100A, Novocure Ltd.), has been shown to be efficacious in the treatment of glioblastoma. 36 The alternating fields are antimitotic. The device is large and cumbersome, and it requires the head to be shaved and numerous electrodes to be connected to the head. This may be yet another field where stentrode-like devices may aid current technology.
Stentrodes have briefly been discussed as above for epilepsy treatment, but there may also one day be a better way of long-term recording allowing the patient to be free of wires, glue, and so on.
The use of stentrodes may also have possible applications in the realm of neurocognitive disorders. Previous studies have explored the use of DBS in hippocampal and medial-temporal regions using open-loop stimulation with stimulation leading to improvements in memory. 15, 35, 48, 51 Recently, researchers reported the use of closed-loop stimulation of lateral temporal cortex for sensing and stimulating the brain during a memory task in 25 neurosurgical patients undergoing intracranial EEG monitoring for refractory epilepsy, demonstrating improved recall. 12 The lateral temporal cortex would be available to stentrode placement via the middle meningeal artery, as shown in Table 1 .
Conclusions
Endovascular delivery of neuromodulating devices appears to be a feasible, minimally invasive technique with therapeutic applications in many fields. The catheter-based techniques utilized today are able to reach most desired locations for therapeutic action. Limitations at this time lie in the development of durable and safe endovascular leads and stentrodes with the capability of wireless transmission.
